Skip to main content

Table 7 BED comparison considering total treatment time for different schedules

From: A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects

RT schedule BED tumor control α/β4 BED acute effects α/β10 BED fibrosis α/β1.7 BED vascular damage α/β2.5
W.B. = whole breast
B.S. = tumor bed side
W.B. B.S. W.B. B.S. W.B. B.S. W.B. B.S.
60 Gy/30 F/6 W
(50 Gy + 10 Gy seq.boost)
68 78 53 60 109 131 90 108
50 Gy/25 F/5 W
(no boost)
68 68 53 53 109 109 90 90
42 Gy/13 F/3W + 1 day
(39 Gy + 3 Gy cc.boost)
68 77 51 56 108 123 86 97
52 Gy/20/F/5 W
(46 Gy + 6 Gy cc.boost)
65 75 49 54 108 135 88 108
UK START TRIAL A
41.6 Gy/13 F/5 W
68 68 48 48 120 120 95 95
UK START TRIAL A
39 Gy/13 F/5W
61 61 43 43 108 108 86 86
  1. boost = concomitant boost; seq.boost = sequential boost; F = fractions; W = weeks